Evidence map›Paper›PMID 33046839›Full record

ReviewNature reviews. Clinical oncology2021

Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives.

Matthijs Oudkerk, ShiYuan Liu, Marjolein A Heuvelmans, Joan E Walter, John K Field

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06473870 (Understanding Lung Cancer Related Risk Factors and Their Impact), which is not on this map. Cited by 294 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
294citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06473870 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Understanding Lung Cancer Related Risk Factors and Their Impact

Typeobservational_patient_registrySponsorBiobizkaia Health Research InstituteRan2024 to 2027Enrolled6,160ConditionsLung Cancer Screening
3 · Its place in the literature

Who cites it

294 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

234 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Matthijs OudkerkInstitute of Diagnostic Accuracy (iDNA), Groningen, Netherlands. m.oudkerk@rug.nl.
ShiYuan LiuDepartment of Radiology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Marjolein A HeuvelmansDepartment of Pulmonary Diseases, Medisch Spectrum Twente, Enschede, Netherlands.
Joan E WalterInstitute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland.
John K FieldRoy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0003-3951-6365

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the past decade, the introduction of molecularly targeted agents and immune-checkpoint inhibitors has led to improved survival outcomes for patients with advanced-stage lung cancer; however, this disease remains the leading cause of cancer-related mortality worldwide. Two large randomized controlled trials of low-dose CT (LDCT)-based lung cancer screening in high-risk populations - the US National Lung Screening Trial (NLST) and NELSON - have provided evidence of a statistically significant mortality reduction in patients. LDCT-based screening programmes for individuals at a high risk of lung cancer have already been implemented in the USA. Furthermore, implementation programmes are currently underway in the UK following the success of the UK Lung Cancer Screening (UKLS) trial, which included the Liverpool Health Lung Project, Manchester Lung Health Check, the Lung Screen Uptake Trial, the West London Lung Cancer Screening pilot and the Yorkshire Lung Screening trial. In this Review, we focus on the current evidence on LDCT-based lung cancer screening and discuss the clinical developments in high-risk populations worldwide; additionally, we address aspects such as cost-effectiveness. We present a framework to define the scope of future implementation research on lung cancer screening programmes referred to as Screening Planning and Implementation RAtionale for Lung cancer (SPIRAL).

Indexed as

Early Detection of CancerCost-Benefit AnalysisDose-Response Relationship, DrugHumansImmune Checkpoint InhibitorsLung NeoplasmsRandomized Controlled Trials as TopicRisk FactorsTomography, X-Ray ComputedImmune Checkpoint Inhibitors

Identifiers

PMID33046839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.